Shenfu Injection for Postoperative Delirium (SFI for POD) (POD)
Primary Purpose
Postoperative Delirium
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Shen-Fu injection
normal saline
Sponsored by
About this trial
This is an interventional prevention trial for Postoperative Delirium
Eligibility Criteria
Inclusion Criteria:
- hip fracture surgery under epidural anesthesia
Exclusion Criteria:
- Severe dementia, hearing/vision impairment, coma, etc., unable to communicate;
- patients with end-stage diseases such as tumor;
- 3 months after myocardial infarction, cerebral infarction;
- severe heart, liver and renal dysfunction.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
SFI intervention group
Control group
Arm Description
shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
Outcomes
Primary Outcome Measures
incidence of postoperative delirium within 7 days
postoperative delirium(POD), assessed with Confusion Assessment Method scale and Richmond Agitation-Sedation Scale together.
Secondary Outcome Measures
non-delirium complications
postoperative complications except for delirium
length of stay
length of hospital stay
pain assessment within 3 days
postoperative pain estimated with Numerical Rating Scale
all-caused mortality within 30 days
short-term follow up
survival in 1 year
long-term follow up
adverse events to shenfu injection
adverse events caused form shenfu injection
Full Information
NCT ID
NCT05179252
First Posted
November 16, 2021
Last Updated
December 20, 2021
Sponsor
Shandong University of Traditional Chinese Medicine
Collaborators
Shandong Institute of Science and Technology Information
1. Study Identification
Unique Protocol Identification Number
NCT05179252
Brief Title
Shenfu Injection for Postoperative Delirium (SFI for POD)
Acronym
POD
Official Title
POD and Postoperative Outcomes in Senile Patients After SFI for Hip Fracture Surgery: A Randomized Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 1, 2022 (Anticipated)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shandong University of Traditional Chinese Medicine
Collaborators
Shandong Institute of Science and Technology Information
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Surgery or trauma may cause serious problem to patients, especially for senile ones, like postoperative delirium or more postoperative complications. Here, we conduct a investigation of SFI for preventing the happening of POD or postoperative complications.
Detailed Description
SFI(Shenfu Injection), a historical medical herbal medicine of traditional Chinese, which may produced much benefit to clinical patients with furtigue after major surgery, because it was a comment sense to think of energy loss if they experience surgical damage. Here, we administrated intravenously SFI into senile patients, who receiving hip fracture surgery, to avoid bad results or serious postoperative outcomes, in case of enhancing recovery after surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Delirium
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
350 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
SFI intervention group
Arm Type
Experimental
Arm Description
shenfu injection used during surgery, day one and two after surgery, 50ml,iv drop.
Arm Title
Control group
Arm Type
Sham Comparator
Arm Description
same volume of normal saline used during surgery, day one and two after surgery, 50ml,iv drop.
Intervention Type
Drug
Intervention Name(s)
Shen-Fu injection
Other Intervention Name(s)
sanjiu yaan
Intervention Description
Chinese patent medicine made by modern technology
Intervention Type
Drug
Intervention Name(s)
normal saline
Other Intervention Name(s)
physiological saline solution
Intervention Description
0.9% normal saline, used for sham control
Primary Outcome Measure Information:
Title
incidence of postoperative delirium within 7 days
Description
postoperative delirium(POD), assessed with Confusion Assessment Method scale and Richmond Agitation-Sedation Scale together.
Time Frame
day 1-7 after surgery, more scores means higher incidence of POD
Secondary Outcome Measure Information:
Title
non-delirium complications
Description
postoperative complications except for delirium
Time Frame
day 1-7 after surgery
Title
length of stay
Description
length of hospital stay
Time Frame
approximately day 1 in hospital to day 7
Title
pain assessment within 3 days
Description
postoperative pain estimated with Numerical Rating Scale
Time Frame
day 1-3 after surgery, higher scores mean more pain.
Title
all-caused mortality within 30 days
Description
short-term follow up
Time Frame
30 days after surgery
Title
survival in 1 year
Description
long-term follow up
Time Frame
1 year discharge from hospital
Title
adverse events to shenfu injection
Description
adverse events caused form shenfu injection
Time Frame
approximately day1-7 after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
75 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
hip fracture surgery under epidural anesthesia
Exclusion Criteria:
Severe dementia, hearing/vision impairment, coma, etc., unable to communicate;
patients with end-stage diseases such as tumor;
3 months after myocardial infarction, cerebral infarction;
severe heart, liver and renal dysfunction.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
zhang weiliang
Phone
13365316885
Email
hezhangweiliang@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
zhang xin
Phone
0531-68616733
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
zhang xin
Organizational Affiliation
Shandong University of Traditional Chinese Medicine
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Shenfu Injection for Postoperative Delirium (SFI for POD)
We'll reach out to this number within 24 hrs